CClinicalTrials.gg
TerminatedNCT02391545Updated Sep 28, 2023Results posted

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

A Phase 1/2 interventional study of Duvelisib and Rituximab in CD20+ Follicular Lymphoma, sponsored by SecuraBio. Terminated at 21 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by SecuraBio · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Sponsor is focusing on studies which can enable registration of duvelisib.
Phase
Phase 1/2
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Two-arm, Phase 1b/2 Study of duvelisib Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma.

Read the detailed description

This is a two-arm, open-label, Phase 1b/2 trial designed to evaluate the safety and efficacy of duvelisib in combination with rituximab and duvelisib in combination with obinutuzumab in subjects with previously untreated CD20+ FL.

The study will be conducted in two parts, a Safety Lead-in (Part 1) followed by a randomized, 2-Stage Design in Part 2. Each treatment arm will be assessed independently for dose limiting toxicity (DLT) within Part 1.

02

Conditions studied

  • CD20+ Follicular Lymphoma

Keywords

  • Follicular Lymphoma
  • Previously Untreated
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of CD20+, follicular lymphoma that has not been treated
  • CD20-immunophenotyping of tumor to document B-cell follicular lymphoma
  • Stage II disease with bulky disease (≥ 7cm lesion), Stage III, or Stage IV disease
  • Disease that requires treatment based on the Investigator's opinion (e.g., meets GELF criteria)
  • At least one measurable lesion that is > 1.5 cm in at least one dimension
  • Eastern Cooperative Oncology Group (ECOG) performance status \<=2 (corresponds to Karnofsky Performance Status [KPS] >=60%)

Exclusion criteria

Exclusion Criteria:

  • Received systemic treatment for lymphoma such as chemotherapy, immunotherapy, radiotherapy, investigational agents, or radioimmunotherapy.
  • Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3B follicular lymphoma
  • Severe allergic or anaphylactic reaction to any monoclonal antibody therapy, murine protein, or known hypersensitivity to any of the study drugs
  • Prior allogeneic hematopoietic stem cell transplant
  • Prior, current or chronic hepatitis B or hepatitis C infection
  • Human immunodeficiency virus (HIV) infection or Human T Cell Lymphotropic Virus 1 (HTLV-1) infection
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Duvelisib and Rituximab

    Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles. Rituximab 375 mg/m2 will be administered intravenously (IV) beginning on Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26.

    Drug: Duvelisib · Drug: Rituximab

  • Experimental
    Duvelisib and Obinutuzumab

    Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules. Duvelisib will be administered orally, twice daily, in 28-day cycles. Obinutuzumab 1000 mg will be administered intravenously (IV) beginning at Cycle 1 (28 day cycles); days 1, 8, 15 and 22. Thereafter, infusions will occur on Day 1 of the even cycles treatment; Cycles 4-26.

    Drug: Duvelisib · Drug: Obinutuzumab

Interventions

  • DrugDuvelisib

    PI3K Inhibitor

    Also known as: Copiktra, IPI-145

  • DrugRituximab

    monoclonal antibody

    Also known as: Rituxan/MabThera®

  • DrugObinutuzumab

    monoclonal antibody

    Also known as: GAZYVA/GAZYVARO™

05

What researchers measure

Primary outcomes

  1. Number of Subjects With Dose Limiting Toxicities (DLTs) - Part 1

    Time frame: 28 days from first dose of study treatment

  2. Complete Response Rate (CRR)- Part 2

    Time frame: Up to 2 years from the first dose of study treatment

Secondary outcomes

  1. Safety: Composite Measure of Safety, as Indicated by Treatment-emergent Adverse Events (TEAEs) and Changes in Safety Laboratory Values

    Composite measure of safety, as indicated by Treatment-emergent adverse events (TEAEs) and changes in safety laboratory values. TEAEs assessed as \>=Grade 3.

    Time frame: Up to 30 days after the last dose of study treatment

  2. Overall Response Rate (ORR)

    Time frame: Up to 2 years from the first dose of study treatment

  3. Duration of Response (DOR)

    The median DOR was non-estimable.

    Time frame: Up to 2 years from the first dose of study treatment

  4. Overall Survival (OS)

    Time frame: Up to 2 years from the first dose of study treatment

  5. Pharmacokinetic (PK): Plasma Concentrations of Duvelisib and IPI-656 (Metabolite)

    Plasma concentrations of Duvelisib and IPI-656 (metabolite)

    Time frame: Every 4 weeks for 16 weeks

06

Results

Posted Jan 8, 2019

Participant flow

Participant flow — Overall Study
MilestoneDuvelisib and ObinutuzumabDuvelisib and Rituximab
Started2728
Completed10
Not completed2628
Withdrew: Death02
Withdrew: Lost to follow-up01
Withdrew: Termination of study by sponsor2020
Withdrew: Withdrawal by subject01
Withdrew: Other reasons64

Outcome measures

PrimaryNumber of Subjects With Dose Limiting Toxicities (DLTs) - Part 1
Time frame:
28 days from first dose of study treatment
Reported as:
Count of participants · Participants
Number of Subjects With Dose Limiting Toxicities (DLTs) - Part 1
ParticipantsDuvelisib and ObinutuzumabDuvelisib and Rituximab
Number of Subjects With Dose Limiting Toxicities (DLTs) - Part 110
PrimaryComplete Response Rate (CRR)- Part 2
Time frame:
Up to 2 years from the first dose of study treatment
Reported as:
Count of participants · Participants
Complete Response Rate (CRR)- Part 2
ParticipantsDuvelisib and ObinutuzumabDuvelisib and Rituximab
Complete Response Rate (CRR)- Part 21110
SecondarySafety: Composite Measure of Safety, as Indicated by Treatment-emergent Adverse Events (TEAEs) and Changes in Safety Laboratory Values

Composite measure of safety, as indicated by Treatment-emergent adverse events (TEAEs) and changes in safety laboratory values. TEAEs assessed as \>=Grade 3.

Time frame:
Up to 30 days after the last dose of study treatment
Reported as:
Count of participants · Participants
Safety: Composite Measure of Safety, as Indicated by Treatment-emergent Adverse Events (TEAEs) and Changes in Safety Laboratory Values
ParticipantsDuvelisib and ObinutuzumabDuvelisib and Rituximab
TEAEs assessed as ≥ Grade 32419
TEAEs ≥ Grade 3 assessed as related to duvelisib2317
TEAEs ≥ Grade 3 assessed as related to anti-CD20112
SecondaryOverall Response Rate (ORR)
Time frame:
Up to 2 years from the first dose of study treatment
Reported as:
Number · participants
Overall Response Rate (ORR)
participantsDuvelisib and ObinutuzumabDuvelisib and Rituximab
Complete Response1110
Partial Response1316
Stable Disease10
SecondaryDuration of Response (DOR)

The median DOR was non-estimable.

Time frame:
Up to 2 years from the first dose of study treatment

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)
Time frame:
Up to 2 years from the first dose of study treatment

No measurements were reported for this outcome.

SecondaryPharmacokinetic (PK): Plasma Concentrations of Duvelisib and IPI-656 (Metabolite)

Plasma concentrations of Duvelisib and IPI-656 (metabolite)

Time frame:
Every 4 weeks for 16 weeks

No measurements were reported for this outcome.

Adverse events

Collected over 35 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duvelisib and Obinutuzumab0/27 (0%)16/27 (59.3%)26/27 (96.3%)
Duvelisib and Rituximab1/28 (3.6%)10/28 (35.7%)27/28 (96.4%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventDuvelisib and ObinutuzumabDuvelisib and Rituximab
PyrexiaGeneral disorders4/272/28
DiarrhoeaGastrointestinal disorders2/274/28
ColitisGastrointestinal disorders2/271/28
Alanine aminotransferase increasedInvestigations2/270/28
RashSkin and subcutaneous tissue disorders2/271/28
Febrile NeutropeniaBlood and lymphatic system disorders1/270/28
OdynophagiaGastrointestinal disorders1/270/28
StomatitisGastrointestinal disorders1/270/28
FatigueGeneral disorders1/270/28
Mucosal InflammationGeneral disorders1/270/28
Most frequent other events
Showing 10 of 63
Most frequent other events
EventDuvelisib and ObinutuzumabDuvelisib and Rituximab
DiarrhoeaGastrointestinal disorders11/2716/28
Alanine aminotransferase increasedInvestigations13/279/28
Aspartate aminotransferase increasedInvestigations13/278/28
NauseaGastrointestinal disorders12/277/28
FatigueGeneral disorders8/279/28
Abdominal PainGastrointestinal disorders8/275/28
VomitingGastrointestinal disorders8/273/28
PyrexiaGeneral disorders8/276/28
RashSkin and subcutaneous tissue disorders7/277/28
CoughRespiratory, thoracic and mediastinal disorders6/277/28

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Duvelisib and ObinutuzumabDuvelisib and RituximabTotal
<=18 years000
Between 18 and 65 years162036
>=65 years11819
Age, Continuous
Age, Continuous(years)Duvelisib and ObinutuzumabDuvelisib and RituximabTotal
Mean58.4 ± 12.3258.2 ± 10.6558.3 ± 11.39
Sex: Female, Male
Sex: Female, Male(Participants)Duvelisib and ObinutuzumabDuvelisib and RituximabTotal
Female161026
Male111829
Region of Enrollment
Region of Enrollment(participants)Duvelisib and ObinutuzumabDuvelisib and RituximabTotal
Belgium639
United States10919
United Kingdom325
Italy112
France347
Spain4913
07

Study locations

21 sites
  • Los Angeles, California 90095, United States
  • Palo Alto, California 94304, United States
  • Hackensack, New Jersey 07601, United States
  • Rochester, New York 14642, United States
  • Dallas, Texas 75246, United States
  • Kortrijk, 8000, Belgium
  • Leuven, 3000, Belgium
  • Wilrijk, 2610, Belgium
  • Clermont-Ferrand, 63003, France
  • Marseille Cedex 05, 13385, France
  • Pessac, 33600, France
  • Rouen Cedex 1, 76038, France
  • Tours Cedex 01, 37044, France
  • Bologna, 40138, Italy
  • Varese, 21100, Italy
  • Badalona, Barcelona 8916, Spain
  • Barcelona, 8097, Spain
  • Madrid, 28222, Spain
  • Salamanca, 37007, Spain
  • Leeds, LS9 7TF, United Kingdom
  • London, NW1 1BU, United Kingdom
08

Registry details

Key details

Study ID
NCT02391545
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Mar 18, 2015
Start date
Dec 2014
Primary completion
Jan 17, 2017
Completion
May 2017
Results posted
Jan 8, 2019
Last update
Sep 28, 2023

Study contacts

Hagop Youssoufian, MD
study chair · Verastem, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion